U.S., Sept. 5 -- ClinicalTrials.gov registry received information related to the study (NCT07154264) titled 'A Study of DZD8586 Combination in CLL/SLL (TAI-SHAN10)' on Aug. 18.
Brief Summary: This is a phase 2 study to investigate the efficacy and safety of DZD8586 in combination in participants with CLL/SLL.
This study consists of two parts: Part A is the safety lead-in phase, and Part B is the dose expansion phase.
Study Start Date: Oct., 2025
Study Type: INTERVENTIONAL
Condition:
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Intervention:
DRUG: DZD8586
DZD8586 will be taken orally once daily on days 1-28 of each cycle.
DRUG: Venetoclax
Venetoclax will be taken orally once daily on days 1-28 starting from cycle 4 day ...